探索嗅觉功能障碍作为头颈癌衰弱与术后结局的标志物
这项前瞻性队列研究在三级学术医疗中心纳入51例头颈癌患者,评估嗅觉功能障碍与衰弱及术后结局的关联。结果显示,尽管患者自报嗅觉正常,59%经心理物理测试存在嗅觉功能障碍,严重嗅觉减退/嗅觉丧失与衰弱风险及术后住院时间延长相关。
要点
- 头颈癌患者中,自报嗅觉正常者经UPSIT测试仍有59%存在可测的嗅觉功能障碍。
- 严重嗅觉减退/嗅觉丧失与衰弱/极衰弱风险增加相关,比值比为1.75(95%CI,1.09-2.80)。
- 严重嗅觉减退/嗅觉丧失与术后住院时间约增加3天相关(β,2.96;95%CI,0.29-5.62)。
核心结论
- 头颈癌患者对嗅觉变化缺乏感知,但嗅觉功能障碍常见,可能作为衰弱的预警标志。
- 本前瞻性队列研究显示嗅觉功能障碍程度与衰弱之间存在剂量依赖关联,并提示嗅觉评估可能作为头颈癌衰弱评估的试金石。
研究设计与样本
- 前瞻性队列研究,纳入2021年2月17日至2021年9月29日在三级学术医疗中心入组的85例符合条件成年患者,最终分析51例原发、未治疗的头颈癌患者,肿瘤起源于黏膜或皮肤。
- 排除有COVID-19、神经认知或原发性嗅觉/味觉障碍病史的患者。
- 采用自报视觉模拟量表(VAS)和心理物理测试(宾夕法尼亚大学嗅觉识别测试,UPSIT)进行前瞻性嗅觉评估,同时进行衰弱评估(风险分析指数,RAI)。
- 采用简短嗅觉障碍问卷阴性陈述(QOD-NS)评估嗅觉特异性生活质量。
主要发现
- 51例患者平均(SD)年龄63(10)岁,39例(77%)为男性,41例(80%)为白人;24例(47%)为衰弱,4例(8%)为极衰弱。
- 自报嗅觉VAS中位数(IQR)为9(8-10),但30例(59%)患者经心理物理测试存在可测的嗅觉功能障碍。
- 自报与心理物理测试之间无有意义的关联(Hodges-Lehmann,<0.001;95%CI,-2至1);46例(90%)患者未报告嗅觉特异性生活质量下降。
- 衰弱患者的中位UPSIT评分较低(Hodges-Lehmann,6;95%CI,2-12)。
- 多变量模型显示,严重嗅觉减退/嗅觉丧失与衰弱/极衰弱的比值比为1.75(95%CI,1.09-2.80),并与住院时间约增加3天相关(β,2.96;95%CI,0.29-5.62)。
关键数值与推荐
- VAS评分范围0-10,0表示无嗅觉,10表示嗅觉正常。
- UPSIT评分范围0-40,评分越高反映嗅觉越好。
- RAI评分范围0-81,评分越高表示衰弱程度越重。
- QOD-NS评分范围0-21,评分越高表示生活质量越差。
临床怎么用
- 作者认为,嗅觉功能障碍可能作为头颈癌衰弱评估的试金石。
- 作者指出,尽管头颈癌患者未察觉嗅觉变化,但嗅觉功能障碍常见,可能作为衰弱的预警标志。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Olfactory dysfunction (OD) is increasingly recognized as a robust marker of frailty and mortality. Despite broad recognition of frailty as a critical component of head and neck cancer (HNC) care, there is no standardized frailty assessment. OBJECTIVE: To assess the prevalence of OD and its association with frailty and postoperative outcomes in HNC. DESIGN, SETTING, AND PARTICIPANTS: In this prospective cohort study with enrollment between February 17, 2021, to September 29, 2021, at a tertiary academic medical center, 85 eligible adult patients with primary, treatment-naive HNC of mucosal or cutaneous origin were included. Patients with a history of COVID-19, neurocognitive, or primary smell/taste disorders were excluded. EXPOSURES: Prospective olfactory assessments (self-reported, visual analog scale [VAS] and psychophysical, University of Pennsylvania Smell Identification Test [UPSIT]) with concurrent frailty assessment (Risk Analysis Index [RAI]) were used. Olfactory-specific quality of life (QOL) was examined with brief Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS). MAIN OUTCOME(S) AND MEASURE(S): The primary outcome was the prevalence of OD as assessed by VAS (0-10, no to normal smell) and UPSIT (0-40, higher scores reflect better olfaction) and its association with frailty (RAI, 0-81, higher scores indicate greater frailty). For surgical patients, secondary outcomes were associations between OD and postoperative length of stay (LOS), 30-day postoperative outcomes, and QOD-NS (0-21, higher scores indicate worse QOL). RESULTS: Among 51 patients with HNC (mean [SD] age, 63 [10] years; 39 [77%] male participants; 41 [80%] White participants), 24 (47%) were frail, and 4 (8%) were very frail. Despite median (IQR) self-reported olfaction by VAS of 9 (8-10), 30 (59%) patients demonstrated measured OD with psychophysical testing. No meaningful association was found between self-reported and psychophysical testing (Hodges-Lehmann, <0.001; 95% CI, -2 to 1); a total of 46 (90%) patients did not report decreased olfaction-specific QOL. Median UPSIT scores were lower in frail patients (Hodges-Lehmann, 6; 95% CI, 2-12). Multivariate modeling demonstrated severe microsmia/anosmia was associated with 1.75 (95% CI, 1.09-2.80) times odds of being frail/very frail and approximately 3 days increased LOS (β, 2.96; 95% CI, 0.29-5.62). CONCLUSIONS AND RELEVANCE: Although patients with HNC are unaware of olfactory changes, OD is common and may serve as a bellwether of frailty. In this prospective cohort study, a dose-dependent association was demonstrated between increasing degrees of OD and frailty, and the potential utility of olfaction was highlighted as a touchstone in the assessment of HNC frailty.
引用
- Mady LJ, De Ravin E, Vohra V, et al. Exploring Olfactory Dysfunction as a Marker of Frailty and Postoperative Outcomes in Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 37498617. doi:10.1001/jamaoto.2023.1935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。